All Phenotypes Pkn3<tm1.1Mrl> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Pkn3^tm1.1Mrl
targeted mutation 1.1, Merck Research Laboratory
MGI:5688854

Summary

5 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺	B6.Cg-Pkn3^tm1.1Mrl Commd10^{Tg(Vav1-icre)A2Kio}	MGI:5688866
cn2	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Pten^tm1Hwu/Pten^tm1Hwu Tg(CD2-icre)4Kio/0	involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca	MGI:5688869
cn3	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0	involves: 129S4/SvJae * C57BL/6 * CBA/J	MGI:5688867
cn4	Pkn3^tm1.1Mrl/Pkn3⁺ Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0	involves: 129S4/SvJae * C57BL/6 * CBA/J	MGI:5688868
cn5	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * CBA/J	MGI:5688862

Allelic Composition	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Commd10^{Tg(Vav1-icre)A2Kio}/Commd10⁺
Genetic Background	B6.Cg-Pkn3^tm1.1Mrl Commd10^{Tg(Vav1-icre)A2Kio}

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Commd10^{Tg(Vav1-icre)A2Kio} mutation (4 available); any Commd10 mutation (25 available)
Pkn3^tm1.1Mrl mutation (0 available); any Pkn3 mutation (54 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

hematopoietic system phenotype ( J:216983 )

N	• hematopoietic stem cell numbers are similar to controls at 6-8 weeks of age and cells perform similar to control cells in a competitive transplantation assay

Allelic Composition	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Pten^tm1Hwu/Pten^tm1Hwu Tg(CD2-icre)4Kio/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pkn3^tm1.1Mrl mutation (0 available); any Pkn3 mutation (54 available)
Pten^tm1Hwu mutation (16 available); any Pten mutation (88 available)
Tg(CD2-icre)4Kio mutation (5 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:216983 )

N	• thymus weight is similar to controls at 6-8 weeks of age unlike in mutant mice wild-type for Pkn3

Allelic Composition	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * CBA/J

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:216983 )

• lifespan after pIpC treatment is shorter than in controls but longer than in mutant nice with one wild-type Pkn3 allele

neoplasm

increased hemolymphoid system tumor incidence ( J:216983 )

• develop myeloproliferative neoplasms in the spleen 2 weeks after pIpC treatment

increased acute lymphoblastic leukemia incidence ( J:216983 )

• all eventually develop T cell acute lymphoblastic leukemia after pIpC treatment at 6 weeks of age

hematopoietic system

enlarged thymus ( J:216983 )

• at 2 weeks after pIpC treatment

• thymus is smaller than in mutant mice with one wild-type Pkn3 allele

enlarged spleen ( J:216983 )

• at 2 weeks after pIpC treatment

extramedullary hematopoiesis ( J:216983 )

• increase in the number of hematopoietic stem cells in the spleen 2 weeks after pIpC treatment

endocrine/exocrine glands

enlarged thymus ( J:216983 )

• at 2 weeks after pIpC treatment

• thymus is smaller than in mutant mice with one wild-type Pkn3 allele

immune system

enlarged thymus ( J:216983 )

• at 2 weeks after pIpC treatment

• thymus is smaller than in mutant mice with one wild-type Pkn3 allele

enlarged spleen ( J:216983 )

• at 2 weeks after pIpC treatment

growth/size/body

enlarged spleen ( J:216983 )

• at 2 weeks after pIpC treatment

Allelic Composition	Pkn3^tm1.1Mrl/Pkn3⁺ Pten^tm1Hwu/Pten^tm1Hwu Tg(Mx1-cre)1Cgn/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * CBA/J

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:216983 )

• lifespan after pIpC treatment is shorter than in controls and in mutant nice with no wild-type Pkn3 alleles

neoplasm

increased hemolymphoid system tumor incidence ( J:216983 )

• develop myeloproliferative neoplasms in the spleen 2 weeks after pIpC treatment

increased acute lymphoblastic leukemia incidence ( J:216983 )

• all eventually develop T cell acute lymphoblastic leukemia after pIpC treatment at 6 weeks of age

hematopoietic system

enlarged thymus ( J:216983 )

• at 2 weeks after pIpC treatment

enlarged spleen ( J:216983 )

• at 2 weeks after pIpC treatment

extramedullary hematopoiesis ( J:216983 )

• increase in the number of hematopoietic stem cells in the spleen 2 weeks after pIpC treatment

endocrine/exocrine glands

enlarged thymus ( J:216983 )

• at 2 weeks after pIpC treatment

immune system

enlarged thymus ( J:216983 )

• at 2 weeks after pIpC treatment

enlarged spleen ( J:216983 )

• at 2 weeks after pIpC treatment

growth/size/body

enlarged spleen ( J:216983 )

• at 2 weeks after pIpC treatment

Allelic Composition	Pkn3^tm1.1Mrl/Pkn3^tm1.1Mrl Tg(Mx1-cre)1Cgn/0
Genetic Background	involves: C57BL/6 * CBA/J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Pkn3^tm1.1Mrl mutation (0 available); any Pkn3 mutation (54 available)
Tg(Mx1-cre)1Cgn mutation (7 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

hematopoietic system phenotype ( J:216983 )

N	• peripheral and bone marrow hematopoietic cell counts are similar to controls at 8 weeks after pIpC treatment

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 12/17/2024 MGI 6.24